From National HTA to Joint Clinical Assessment: Exploring Similarities and Differences in Comparator and Outcome Selection Across Six European Health Technology Assessment Agencies

About this session

ISSUE: The HTA Regulation (HTAR) came into effect on January 2025 and the first Joint Clinical Assessments (JCA) on medicinal products started. To understand the predictability of the PICOs (Patient Population, Intervention, Comparators and Outcomes) in JCAs, comparison are made between the Outcomes and Comparators requested by six European HTA bodies on 21 oncology/ATMP drugs in a retrospective study.

Speakers

• 

  Anne Willemsen

  Zorginstituut Nederland

  Moderator

• RA

  Roisin Adams

  Panelist

• KM

  Keltoum Merroune

  Haute Autorité de Santé

  Panelist

• SS

  Stephanie Said

  Panelist